Evaluation
*
*
*
*
*
*
Please use the scale: 1=Poor, 2=Fair, 3=Satisfactory, 4=Good, 5=Excellent
12345
Discuss novel diagnostic strategies, updated guidelines, and the principles of precision medicine for the cystic fibrosis patient
Analyze the improved disease progression in cystic fibrosis patients who have received CFTR modulation therapy
Review the most current and emerging clinical trial data for CFTR modulation, as well as combination therapies, in the patient with cystic fibrosis
Optimize your strategies to manage and monitor CFTR modulator-treated cystic fibrosis patients
*
Please use the scale: 1=Strongly Disagree, 2=Disagree, 3=Neutral, 4=Agree, 5= Strongly Agree
12345
Overall, I was satisfied with this program
Overall, the content was relevant to my practice
The information presented was without promotional or commercial bias
The information presented was scientifically rigorous and evidence based
The information presented provided appropriate and effective opportunities for active learning (discussion, Q&A)
The information presented promoted improvements or quality in health care
The quality of the educational process was satisfactory and appropriate
The format of the discussion was relevant and enhanced my knowledge of the subject
The format of the discussion was relevant and enhanced my competence to treat patients with Cystic Fibrosis
The faculty/speakers were knowledgeable and presented the information clearly
*
NeverNot OftenSometimesOftenAlwaysN/A
Develop new strategies to manage multiple clinical manifestations in patients with cystic fibrosis
Recognize the changes in lung pathophysiology after initiating genetically-targeted pharmacotherapies into patient treatment
Recognize the degree of pulmonary dysfunction can be highly variable, even among individuals with the same genotype
*
NeverNot OftenSometimesOftenAlwaysN/A
Develop new strategies to manage multiple clinical manifestations in patients with cystic fibrosis
Recognize the changes in lung pathophysiology after initiating genetically-targeted pharmacotherapies into patient treatment
Recognize the degree of pulmonary dysfunction can be highly variable, even among individuals with the same genotype
*
PoorFairGoodVery GoodExcellent
Susanna A. McColley, MD (Program Chair)
Jane Davies, MD
Felix Ratjen, MD PhD
Manu Jain, MD